Sonnet Total Assets vs Net Receivables Analysis
| SONN Stock | USD 3.22 0.34 11.81% |
Sonnet Biotherapeutics financial indicator trend analysis is much more than just breaking down Sonnet Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonnet Biotherapeutics is a good investment. Please check the relationship between Sonnet Biotherapeutics Total Assets and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
Total Assets vs Net Receivables
Total Assets vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonnet Biotherapeutics Total Assets account and Net Receivables. At this time, the significance of the direction appears to have no relationship.
The correlation between Sonnet Biotherapeutics' Total Assets and Net Receivables is 0.07. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Sonnet Biotherapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Sonnet Biotherapeutics' Total Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Sonnet Biotherapeutics Holdings are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Assets i.e., Sonnet Biotherapeutics' Total Assets and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.07 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Total Assets
Total assets refers to the total amount of Sonnet Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sonnet Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Net Receivables
Most indicators from Sonnet Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. At this time, Sonnet Biotherapeutics' Tax Provision is very stable compared to the past year. As of the 9th of August 2025, Enterprise Value is likely to grow to about 20 M, while Selling General Administrative is likely to drop about 2.4 M.
| 2021 | 2022 | 2023 | 2025 (projected) | Other Operating Expenses | 30.0M | 18.9M | 11.9M | 4.5M | Total Revenue | 349.9K | 147.8K | 18.6K | 42.6M |
Sonnet Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Sonnet Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonnet Biotherapeutics fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 8.0M | 29.0M | 5.8M | 5.4M | 2.8M | 28.3M | |
| Short Long Term Debt Total | 353.3K | 125.9K | 256.0K | 203.9K | 130.9K | 9.8M | |
| Total Current Liabilities | 4.7M | 6.7M | 8.2M | 5.5M | 3.2M | 12.4M | |
| Total Stockholder Equity | 3.0M | 22.3M | (2.5M) | (226.0K) | (485.7K) | 8.6M | |
| Property Plant And Equipment Net | 273.8K | 182.3K | 302.8K | 227.1K | 143.9K | 5.1M | |
| Current Deferred Revenue | 500K | 516.4K | 166.4K | 18.6K | 1.1M | 1.1M | |
| Net Debt | (7.0M) | (27.5M) | (2.8M) | (2.1M) | (18.6K) | 9.3M | |
| Accounts Payable | 2.1M | 3.8M | 4.8M | 2.2M | 2.2M | 2.3M | |
| Non Current Assets Total | 356.8K | 182.3K | 416.1K | 691.2K | 653.1K | 27.0M | |
| Liabilities And Stockholders Equity | 8.0M | 29.0M | 5.8M | 5.4M | 2.8M | 28.3M | |
| Non Current Liabilities Total | 250.0K | 30.6K | 203.9K | 130.9K | 46.6K | 8.1M | |
| Other Stockholder Equity | 39.7M | 83.9M | 88.9M | 110.0M | 117.2M | 60.9M | |
| Total Liab | 5.0M | 6.7M | 8.4M | 5.7M | 3.3M | 20.5M | |
| Total Current Assets | 7.6M | 28.8M | 5.4M | 4.7M | 2.1M | 1.3M | |
| Short Term Debt | 103.2K | 95.3K | 52.1K | 73.0K | 84.3K | 12.8M | |
| Common Stock | 1.5K | 6.0K | 554.0 | 175.0 | 65.0 | 354.35 | |
| Retained Earnings | (36.7M) | (61.7M) | (91.4M) | (110.2M) | (117.7M) | (60.0M) | |
| Cash | 7.3M | 27.6M | 3.1M | 2.3M | 149.5K | 497.9K | |
| Non Currrent Assets Other | 83.0K | (182.3K) | 113.3K | 464.2K | 509.1K | 2.7M | |
| Cash And Short Term Investments | 7.3M | 27.6M | 3.1M | 2.3M | 149.5K | 497.9K | |
| Other Current Assets | 575.5K | 2.4M | 4.0M | 1.7M | 1.2M | 151.2K | |
| Common Stock Shares Outstanding | 3.8K | 10.0K | 24.7K | 129.8K | 655.2K | 418.0 | |
| Other Current Liab | 2.1M | 2.3M | 3.2M | 3.2M | 942.5K | 2.7M | |
| Property Plant And Equipment Gross | 273.8K | 182.3K | 302.8K | 227.1K | 143.9K | 5.0M | |
| Net Tangible Assets | 7.4M | 3.0M | 22.3M | (2.5M) | 8.5M | 9.0M | |
| Capital Lease Obligations | 207.2K | 125.1K | 255.2K | 203.9K | 130.9K | 15.2K |
Pair Trading with Sonnet Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sonnet Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sonnet Stock
| 0.63 | MRK | Merck Company | PairCorr |
| 0.8 | INBX | Inhibrx Biosciences, | PairCorr |
| 0.65 | LNDNF | Lundin Energy AB | PairCorr |
Moving against Sonnet Stock
The ability to find closely correlated positions to Sonnet Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sonnet Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sonnet Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sonnet Biotherapeutics Holdings to buy it.
The correlation of Sonnet Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sonnet Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sonnet Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sonnet Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.07) | Revenue Per Share | Quarterly Revenue Growth 52.688 | Return On Assets | Return On Equity |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.